Trajectories following Impella 5.5 support are associated with initial presentation acuity
Artificial Organs · 2025
DOI: 10.1111/aor.14867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Jean-Luc A Maigrot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular, and Thoracic Institute, …. Hauptthemen laut MEDLINE: Heart-Assist Devices, Shock, Cardiogenic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Impella 5.5 is a temporary left ventricular assist device utilized to support patients with cardiogenic shock and those undergoing high‐risk cardiac interventions.
Methods
From October 2019 to January 2023, 226 patients received Impella 5.5 support at Cleveland Clinic main campus. Patients were stratified by Society for Cardiovascular Angiography and Interventions (SCAI) shock stages. Immediate post‐Impella 5.5 trajectories were compared across groups. Trajectories were defined as mortality on Impella 5.5, transition to advanced heart failure therapies (durable left ventricular assist device/heart transplantation), or survival to Impella 5.5 removal without advanced therapies.
Results
Overall, 148 (65%) patients with cardiogenic shock and 78 (35%) undergoing high‐risk cardiac interventions received Impella 5.5 support. SCAI stage was A in 63 (28%), B in 10 (4.4%), C in 29 (13%), D in 104 (46%), and E in 20 (8.8%). Mortality on Impella 5.5 was highest in SCAI stage E (A: 3.2%, B: 10%, C: 14%, D: 27%, E: 35%; p < 0.01). Transition to advanced therapies (durable left ventricular assist device or heart transplantation) was highest in SCAI stages C‐D (A: 1.6%, B: 0.0%, C: 45%, D: 36%, E: 20%; p < 0.01). Survival to Impella removal without advanced therapies was highest in SCAI stages A‐B (A: 95%, B: 90%, C: 41%, D: 38%, E: 45%; p < 0.01).
Conclusions
Stratification by presentation acuity in candidates for Impella 5.5 insertion may help identify which patients may and may not benefit from this escalation of tailored temporary mechanical circulatory support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Cardiovascular Medicine, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Zitieren
APA
Maigrot, J. A., Starling, R. C., Soltesz, E. G., Smedira, N. G., Tong, M. Z. Y., Unai, S., Bhat, P., Moros, D., Blackstone, E. H., & Weiss, A. J. (2025). Trajectories following Impella 5.5 support are associated with initial presentation acuity. Artificial Organs. https://doi.org/10.1111/aor.14867
Vancouver
Maigrot JA, Starling RC, Soltesz EG, Smedira NG, Tong MZY, Unai S, et al. Trajectories following Impella 5.5 support are associated with initial presentation acuity. Artificial Organs. 2025. doi:10.1111/aor.14867
BibTeX
@article{Maigrot2025,
author = {Maigrot, Jean-Luc A and Starling, Randall C and Soltesz, Edward G and Smedira, Nicholas G and Tong, Michael Z Y and Unai, Shinya and Bhat, Pavan and Moros, David and Blackstone, Eugene H and Weiss, Aaron J},
title = {Trajectories following Impella 5.5 support are associated with initial presentation acuity},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14867}
}
EUVIMED